Kyle Piskel Sells 4,290 Shares of Adaptive Biotechnologies (NASDAQ:ADPT) Stock

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) CFO Kyle Piskel sold 4,290 shares of Adaptive Biotechnologies stock in a transaction that occurred on Monday, January 12th. The stock was sold at an average price of $18.00, for a total transaction of $77,220.00. Following the completion of the sale, the chief financial officer owned 216,637 shares of the company’s stock, valued at $3,899,466. This trade represents a 1.94% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Kyle Piskel also recently made the following trade(s):

• On Friday, November 28th, Kyle Piskel sold 162,820 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $19.50, for a total transaction of $3,174,990.00.
• On Monday, November 17th, Kyle Piskel sold 238 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $14.05, for a total transaction of $3,343.90.

Adaptive Biotechnologies Price Performance

Shares of ADPT opened at $17.78 on Friday. The company’s fifty day moving average price is $16.54 and its 200-day moving average price is $14.46. Adaptive Biotechnologies Corporation has a 1-year low of $6.26 and a 1-year high of $20.76. The firm has a market capitalization of $2.71 billion, a PE ratio of -32.93 and a beta of 2.18.

Adaptive Biotechnologies (NASDAQ:ADPT) last issued its quarterly earnings results on Wednesday, November 5th. The company reported ($0.15) EPS for the quarter, topping analysts’ consensus estimates of ($0.16) by $0.01. The company had revenue of $93.97 million during the quarter, compared to analysts’ expectations of $58.76 million. Adaptive Biotechnologies had a negative return on equity of 58.40% and a negative net margin of 31.50%.The firm’s revenue was up 102.4% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($0.22) EPS. As a group, research analysts anticipate that Adaptive Biotechnologies Corporation will post -0.92 EPS for the current fiscal year.

Analyst Ratings Changes

Several brokerages recently weighed in on ADPT. BTIG Research increased their price target on shares of Adaptive Biotechnologies from $19.00 to $21.00 and gave the stock a “buy” rating in a report on Thursday, November 6th. Piper Sandler increased their price objective on shares of Adaptive Biotechnologies from $15.00 to $20.00 and gave the stock an “overweight” rating in a research note on Wednesday, October 15th. Guggenheim started coverage on shares of Adaptive Biotechnologies in a research report on Tuesday, September 30th. They set a “buy” rating and a $20.00 target price for the company. JPMorgan Chase & Co. increased their price target on Adaptive Biotechnologies from $17.00 to $20.00 and gave the stock an “overweight” rating in a research report on Thursday, November 6th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Adaptive Biotechnologies in a research note on Wednesday, October 8th. Nine investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $17.11.

Institutional Trading of Adaptive Biotechnologies

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Ameriprise Financial Inc. raised its position in shares of Adaptive Biotechnologies by 84.3% in the third quarter. Ameriprise Financial Inc. now owns 5,971,706 shares of the company’s stock worth $89,337,000 after acquiring an additional 2,731,648 shares during the period. Arrowstreet Capital Limited Partnership increased its stake in shares of Adaptive Biotechnologies by 544.0% in the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 2,441,402 shares of the company’s stock valued at $36,523,000 after purchasing an additional 2,062,282 shares in the last quarter. Summit Partners Public Asset Management LLC purchased a new position in shares of Adaptive Biotechnologies in the 3rd quarter valued at about $14,934,000. First Trust Advisors LP raised its holdings in Adaptive Biotechnologies by 4,802.2% in the 2nd quarter. First Trust Advisors LP now owns 741,306 shares of the company’s stock worth $8,636,000 after purchasing an additional 726,184 shares during the period. Finally, Peregrine Capital Management LLC purchased a new position in Adaptive Biotechnologies during the second quarter worth approximately $8,187,000. Institutional investors and hedge funds own 99.17% of the company’s stock.

About Adaptive Biotechnologies

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.